Literature DB >> 34083782

SETDB1, a new target for immunotherapy.

Ulrike Harjes1.   

Abstract

Entities:  

Year:  2021        PMID： 34083782     DOI： 10.1038/s41568-021-00373-x

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.

Authors:  Gabriel K Griffin; Jingyi Wu; Arvin Iracheta-Vellve; James C Patti; Jeffrey Hsu; Thomas Davis; Deborah Dele-Oni; Peter P Du; Aya G Halawi; Jeffrey J Ishizuka; Sarah Y Kim; Susan Klaeger; Nelson H Knudsen; Brian C Miller; Tung H Nguyen; Kira E Olander; Malvina Papanastasiou; Suzanna Rachimi; Emily J Robitschek; Emily M Schneider; Mitchell D Yeary; Margaret D Zimmer; Jacob D Jaffe; Steven A Carr; John G Doench; W Nicholas Haining; Kathleen B Yates; Robert T Manguso; Bradley E Bernstein
Journal:  Nature       Date:  2021-05-05       Impact factor: 69.504
  1 in total
  2 in total

1.  Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors.

Authors:  Xin Lin; Min Xiao; Zhitao Chen; Chenchen Ding; Ting Zhang; Qiyong Li
Journal:  J Oncol       Date:  2022-05-23       Impact factor: 4.501

2.  TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway.

Authors:  Hongyu Gu; Shunqin Zhu; Cheng Peng; Zekun Wei; Yang Shen; Chaoyu Yuan; He Yang; Hongjuan Cui; Liqun Yang
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.